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196 Prevalence of undiagnosed pre-diabetes and diabetes in a
UK cohort of young people with cystic ﬁbrosis
L. Selby1, T. Rootsey1, R.M. Williams2,3, K.K. Ong4, D. McShane3. 1University of
Cambridge, School of Clinical Medicine, Cambridge, United Kingdom; 2University
of Cambridge, Paediatrics, Cambridge, United Kingdom; 3Cambridge University
Hospitals NHS Foundation Trust, Childrens Services, Cambridge, United Kingdom;
4University of Cambridge, MRC Epidemiology Unit, Cambridge, United Kingdom
Objectives: To determine prevalence of diabetes (DM) and prediabetes (PD) in young
people not diagnosed with CFRD from the UK national data set.
Methods: The UK national CF data set (2007 to 2012) recording annual height, weight,
BMI, % predicted FEV1 and FVC, and HbA1c was interrogated. Young people up to
age 23 yr were included. HbA1c values >6.5% and 5.7−6.5% were used to deﬁne
‘undiagnosed’ DM and PD, respectively in patients not labelled as having CFRD.
Prevalence of PD and DM and %FEV1 were determined by age group using the ﬁrst
visit values for each individual.
Results: 3759 patients (1627 males, 87.5% with DF508 mutations, median (range) age
14.5 (4.5−23)y were included. Prevalences of known CFRD, and undiagnosed PD and
DM are shown in Table 1.
Table 1: Prevalences of known CFRD and undiagnosed (pre)diabetes in 3759 patients at ﬁrst encounter
Age group
5−10 yrs
(n = 801)
11−16 yrs
(n = 1121)
17−23 yrs
(n = 1837)
FEV1 mean, % [SD] 89.8 [17.0] 80.9 [18.9] 70.5 [24.1]
BMI SDS mean [SD] +0.05 [1.0] −0.11 [1.1] −0.45 [1.2]
Known CFRD, n (%) 16 (2) 122 (10.9) 485 (26.4)
Undiagnosed prediabetes (HbA1c 5.7−6.5), n (%) 300 (38.2) 445 (44.5) 617 (45.6)
Undiagnosed diabetes (HbA1c >6.5), n (%) 14 (1.8) 58 (5.8) 89 (6.6)
In cross-sectional analyses adjusted for gender, age, genotype and BMI, %FEV1 was
inversely associated with HbA1c, B = −5.0 (95%CI −6.0 to −3.0, p< 0.0001). HbA1c
accounted for 22% of the variance in FEV1.
Conclusion: In this large UK data set, an additional 6.6% of CF patients aged 16−23 y
would be diagnosed with diabetes based on HbA1c values. Furthermore, the prevalence
of PD was high across all age groups and was associated with lower %FEV1.
Acknowledgement: We are grateful to the CF trust for sharing the UK national data
set. https://www.cysticﬁbrosis.org.uk/
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Objectives: The World Health Organisation FRAX® tool (http://www.shef.ac.uk/
FRAX/) estimates 10 year fracture risk based on clinical and bone mineral density
(BMD) data, but is only validated in ages 40−90 years. We compared UK National
Osteoporosis Group Guidelines (NOGG) treatment recommendations based on
FRAX 10 year fracture risk and age with those based on UK CF Trust (CFT)
guidelines.
Methods: The FRAX tool was used to estimate 10 year risk of major fracture
based on gender, smoking, steroid use, history of previous fracture, body mass
index (BMI) ± DEXA BMD for Bristol Adult CF Centre (UK) patients >18 years
old. NOGG treatment recommendations based on FRAX 10 year risk and age were
compared with those from CFT Guidelines.
Results: 103 patients (53 males) with mean age 29 years (range 18−59) had
complete data sets. 37% had signiﬁcant steroid use, 9% smoked and 2% had
previous fracture. There was agreement between FRAX/NOGG (with BMD) and
CF trust guidelines in 93 cases (90%); discordance was not associated with age,
steroids, previous fracture or BMI. Where FRAX/NOGG without BMD measure-
ment estimated low risk of major fracture (n = 10), recommendation not to intervene
was not affected by BMD measurement and was concordant with CFT guidelines.
Conclusion: There is good correlation between FRAX/NOGG and CF Trust
treatment recommendations for low BMD. FRAX 10 year fracture risk may be
a useful concept for discussing treatment options with people with CF (who often
have a high treatment burden) particularly in younger/low BMI patients who may
not have reached peak BMD. Those with low risk FRAX 10 year fracture estimates
before BMD measurements may not require DEXA.
198 The prevalence of DF508 in cystic ﬁbrosis patients with low
bone mineral density in Republic of Macedonia
T. Jakovska-Maretti1, S. Fustik2. 1University Pediatric Clinic, CF Center, Skopje,
Macedonia, the Former Yugoslav Republic of; 2University Pediatric Clinic, Skopje,
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Introduction: Reduced bone mass density (BMD) is frequent in patients with
cystic ﬁbrosis (CF). Pathogenesis of CF bone disease is multifactorial. Many studies
suggest that there is genetic component, independent of the disease severity and
nutritional deﬁcits.
Aim: To determine the prevalence and identify determinants of reduced BMD in
CF patients.
Material and Methods: The study included 79 CF patients (range 5−36 y.). BMD
was measured via dual-energy x-ray absorptiometry (DXA) scan. Vitamin D level
was assessed by plasma 25OHD levels (<10 ng/ml and <20 ng/ml) were deﬁned as
severe and mild deﬁciency.
Results: 41 CF patients were homozygote for DF508del mutation, 68.4% have lower
BMD (−2.1 ±0.25SD), 7 with severe osteoporosis. 25OHD was <10 ng/ml in 7.3%,
and <20 ng/ml 39% homozygote CF patients. In group with heterozygote for DF508
(29 CF patients) 74% have low BMD (−1.7 ±0.3SD), 7 with osteoporosis. Severe
deﬁciency of 25OHD <10 ng/ml have 13.8% and 51.7% have levels <20 ng/ml. 9
CF patients have other mutations, 62.5% have low BMD (−0.56 ±0.3SD), 2 of
them have osteoporosis. There was none patient with severe deﬁciency of 25OHD,
and 33% has levels <20 ng/ml.
Conclusion: The DF508 del genotype was associated with lower value of BMD.
Reduced bone mineral density in cystic ﬁbrosis is associated with a number of
factors including DF508 del genotype, deﬁciency of vitamin D, lung disease severity
and malnutrition.
199 Arterial stiffness in an ageing cystic ﬁbrosis (CF) population
attending the All Wales Adult Cystic Fibrosis Centre (AWACFC)
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Background: The life expectancy of patients with CF is increasing and as a result
so is the risk of secondary complications. Ageing, systemic inﬂammation and CF-
Related Diabetes (CFRD) are all cardiovascular risk factors seen in CF patients.
Arterial stiffness is a marker of cardiovascular risk and is independently related to
ageing, systemic inﬂammation and diabetes in non CF patients. We hypothesized
that arterial stiffness would be greater in the adult CFRDM population compared
to CF normal glucose tolerant subjects (CFNGT) and healthy non-CF controls.
Methods: Arterial Stiffness, measured by augmentation index (Aix) and pulse wave
velocity (PWV) (SphygmoCor), blood pressure and lung function was measured in
64 CF adults from the AWCFC. Sixteen healthy age matched non-CF controls were
recruited. Non-parametric and parametric tests were used in the analysis of results.
Results: Patients with CF had greater Aix and PWV than controls (p< 0.05) but
were similar in age, BMI and mean arterial pressure. Of the CF population, 42
had CFRD or CF impaired glucose tolerance (CFIGT) and 22 had CF with normal
glucose tolerance (CFNGT). They were similar in age, BMI, lung function and
blood pressure. Patients with CFRD/CFIGT had greater mean (SD) aortic PWV,
6.1 (1.6) than the CFNGT group, 5.4 (0.7) (p = 0.03).
Conclusion: The results show increased arterial stiffness as measured by Aix and
PWV is present in CF and to a greater degree in CFRD in comparison to healthy
controls. The ﬁnding of increased PWV suggests premature vascular ageing within
the CF population. Greater awareness of cardiovascular risk prevention is therefore
needed in this population.
